Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Glory Health Industry Limited
國瑞健康產業有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2329)

GRANT OF WAIVER FROM STRICT COMPLIANCE WITH RULES 3.10(1), 3.10(A) AND 3.21 OF THE LISTING RULES

Reference is made to the announcements of Glory Health Industry Limited (the "**Company**") dated June 10, 2025 (the "**June Announcement**") and December 1, 2025 (the "**December Announcement**", together with the June Announcement, the "**Announcements**") in relation to, among others, the resignation of Mr. Yuan Hao ("**Mr. Yuan**") as an independent non-executive director of the Company with effect from June 10, 2025 and the appointment of Mr. Wang Shiyu ("**Mr. Wang**") as an independent non-executive Director with effect from December 1, 2025. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

As disclosed in the Announcements, following Mr. Yuan's resignation on June 10, 2025, the Company has taken proactive measures to identify suitable candidates with relevant background, expertise and experience to fill the vacancies on the Board. However, due to (i) candidates' concerns about the current operating conditions of the property sector in the People's Republic of China; and (ii) the appointment terms required by candidates not being in line with the Company's recruitment standards, the Company needs additional time to identify potential suitable candidates. Consequently, the Company submitted an application to the Stock Exchange on September 9, 2025 for a waiver from strict compliance with Rules 3.10(1), 3.10A and 3.21 of the Listing Rules (the "**Waiver**") until December 1, 2025 and on December 1, 2025, the Company appointed Mr. Wang as an independent non-executive Director.

At the time of issuing the December Announcement, the Company had not yet been granted the Waiver. On December 4, 2025, following the appointment of Mr. Wang, the Stock Exchange granted the Waiver, extending the grace period for the Company to re-comply with Rules 3.10(1), 3.10A and 3.21 of the Listing Rules to December 1, 2025, subject to the disclosure of the details and reasons for the Waiver by way of an announcement. Shareholders and potential investors should note that the Waiver granted is subject to change or withdrawal by the Stock Exchange if the Company's situation changes.

By Order of the Board
Glory Health Industry Limited
Zhang Zhangsun
Chairman

Beijing, the PRC, December 11, 2025

As at the date of this announcement, the Board comprises Mr. Zhang Zhangsun, Ms. Ruan Wenjuan, Mr. Yang Huabin, Mr. Feng Yang and Mr. Zhao Yuhong as executive Directors; and Ms. Chen Jinrong, Mr. Deng Zhidong and Mr. Wang Shiyu as independent non-executive Directors.